Immune-related cutaneous adverse events due to checkpoint inhibitors.

Autor: Wang E; Department of Pediatrics, National Jewish Health, Denver, Colorado., Kraehenbuehl L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Swim Across America/Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Ketosugbo K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Kern JA; Cancer Center, Division of Oncology, Department of Medicine, National Jewish Health, Denver, Colorado., Lacouture ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Weill Cornell Medical College, New York, New York., Leung DYM; Department of Pediatrics, National Jewish Health, Denver, Colorado. Electronic address: leungd@njhealth.org.
Jazyk: angličtina
Zdroj: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2021 Jun; Vol. 126 (6), pp. 613-622. Date of Electronic Publication: 2021 Feb 17.
DOI: 10.1016/j.anai.2021.02.009
Abstrakt: Objective: To familiarize the reader with the most common cutaneous adverse events with immune checkpoint inhibitors (CPIs) and their grading and treatment.
Data Sources: Recent research articles, relevant review articles, and case series/reports in English from the PubMed database mostly, from 2010 onward.
Study Selections: Most data are from retrospective studies and case series. Older studies regarding the mechanism were included if they were of particular importance.
Results: An understanding of this review should enable the reader to identify specific skin disorders in patients receiving immune CPIs, grade the adverse event, and be able to treat or refer the patient as needed.
Conclusion: Allergists/immunologists need to be familiar with these immune-related cutaneous adverse events because their incidence will increase with the ever-expanding use of CPIs and, in particular, because patients will certainly continue to be referred suspecting drug allergies.
(Copyright © 2021 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE